Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Analysts at HC Wainwright raised their Q2 2025 earnings estimates for Nuvectis Pharma in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.60) EPS and FY2028 earnings at ($1.90) EPS.

Other equities analysts have also recently issued research reports about the company. Maxim Group started coverage on Nuvectis Pharma in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $17.00 price target on the stock. Laidlaw began coverage on Nuvectis Pharma in a research note on Monday, March 17th. They set a “buy” rating and a $19.00 price target for the company.

Nuvectis Pharma Trading Down 2.5 %

NVCT stock opened at $8.99 on Friday. The company has a market capitalization of $212.48 million, a P/E ratio of -7.75 and a beta of -0.11. The business has a 50 day simple moving average of $8.99 and a 200-day simple moving average of $7.22. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03.

Institutional Trading of Nuvectis Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new stake in shares of Nuvectis Pharma during the 4th quarter valued at about $34,000. Blue Zone Wealth Advisors LLC purchased a new stake in shares of Nuvectis Pharma during the first quarter valued at approximately $102,000. Nations Financial Group Inc. IA ADV raised its stake in shares of Nuvectis Pharma by 35.0% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock valued at $73,000 after purchasing an additional 3,500 shares during the period. Baxter Bros Inc. lifted its position in shares of Nuvectis Pharma by 20.0% during the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Nuvectis Pharma during the 4th quarter worth $103,000. 96.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri bought 12,444 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The shares were acquired at an average cost of $8.59 per share, with a total value of $106,893.96. Following the transaction, the insider now owns 2,896,565 shares of the company’s stock, valued at $24,881,493.35. This represents a 0.43 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 35.78% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.